Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts
- PMID: 23466908
- PMCID: PMC3916146
- DOI: 10.1086/669865
Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts
Abstract
Objective: To determine prevalence, predictors, and outcomes of infection due to Escherichia coli sequence type ST131.
Design: Retrospective cohort.
Setting: All healthcare settings in Olmsted County, Minnesota (eg, community hospital, tertiary care center, long-term care facilities, and ambulatory clinics).
Patients: Ambulatory and hospitalized children and adults with extraintestinal E. coli isolates.
Methods: We analyzed 299 consecutive, nonduplicate extraintestinal E. coli isolates submitted to Olmsted County laboratories in February and March 2011. ST131 was identified using single-nucleotide polymorphism polymerase chain reaction and further evaluated through pulsed-field gel electrophoresis. Associated clinical data were abstracted through medical record review.
Results: Most isolates were from urine specimens (90%), outpatients (68%), and community-associated infections (61%). ST131 accounted for 27% of isolates overall and for a larger proportion of those isolates resistant to fluoroquinolones (81%), trimethoprim-sulfamethoxazole (42%), gentamicin (79%), and ceftriaxone (50%). The prevalence of ST131 increased with age (accounting for 5% of isolates from those 11-20 years of age, 26% of isolates from those 51-60 years of age, and 50% of isolates from those 91-100 years of age). ST131 accounted for a greater proportion of healthcare-associated isolates (49%) than community-associated isolates (15%) and for fully 76% of E. coli isolates from long-term care facility (LTCF) residents. Multivariable predictors of ST131 carriage included older age, LTCF residence, previous urinary tract infection, high-complexity infection, and previous use of fluoroquinolones, macrolides, and extended-spectrum cephalosporins. With multivariable adjustment, ST131-associated infection outcomes included receipt of more than 1 antibiotic (odds ratio [OR], 2.54 [95% confidence interval (CI), 1.25-5.17]) and persistent or recurrent symptoms (OR, 2.53 [95% CI, 1.08-5.96]). Two globally predominant ST131 pulsotypes accounted for 45% of ST131 isolates.
Conclusions: ST131 is a dominant, antimicrobial-resistant clonal group associated with healthcare settings, elderly hosts, and persistent or recurrent symptoms.
Conflict of interest statement
Figures


Comment in
-
Who is leading this dance? Understanding the spread of Escherichia coli sequence type 131.Infect Control Hosp Epidemiol. 2013 Apr;34(4):370-2. doi: 10.1086/669874. Epub 2013 Feb 13. Infect Control Hosp Epidemiol. 2013. PMID: 23466909 Free PMC article. No abstract available.
References
-
- Coque T, Baquero F, Canton R. Increasing prevalence of ESBL-producing enterobacteriaceae in Europe. Eurosurveillance. 2008;13:1–11. - PubMed
-
- Nicolas-Chanoine M-H, Blanco J, Leflon-Guibout V, et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother. 2008;61:273–281. - PubMed
-
- Peirano G, Pitout J. Molecular epidemiology of Escherichia coli producing CTX-M-beta lactamases: the wordwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents. 2009;35:316–321. - PubMed
-
- Johnson J, Johnston B, Clabots C, Kuskowski M, Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis. 2010;51:286–294. - PubMed
-
- Yokota S, Sato T, Okubo T, et al. Prevalence of fluoroquinolone-resistant Escherichia coli O25:H4-ST131 (CTX-M-15-nonproducing) strains isolated in Japan. Chemother. 2012;58:52–59. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources